Consolidated Statements of Operations and Comprehensive loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 207,709	$ 91,120
Research and development expenses (Note 12)	(1,935,085)	(1,390,545)
Selling and marketing expenses	(92,053)	(15,656)
General and administrative expenses (Note 13)	(5,080,725)	(8,625,959)
Loss from operations	(6,900,154)	(9,941,040)
Financing income, net	2,746	15,259
Other loss (Note 8)	(151,015)
Loss before equity in net loss of equity investments	(7,048,423)	(9,925,781)
Less: Share in net gain (loss) of equity investments	(1,977)	(20,594)
Net loss	(7,050,400)	(9,946,375)
Net loss attributable to non-controlling interests	71,052	3,977
Net loss attributable to the Company’s stockholders	$ (6,979,348)	$ (9,942,398)
Net loss per share attributable to common stockholders - Basic	$ (0.00)	$ (0.00)
Net loss per share attributable to common stockholders - Diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding used in computing basic net loss per share	520,060,275,576	497,734,439,960
Weighted average number of shares outstanding used in computing diluted net loss per share	520,060,275,576	497,734,439,960
Comprehensive loss:
Other comprehensive income - Foreign currency translation adjustments	$ (28,411)	$ 5,644
Comprehensive loss	(7,078,811)	(9,940,731)
Net - loss attributable to non-controlling interests	71,052	3,977
Other comprehensive income to attributable to non-controlling interests	13,243	(2,760)
Comprehensive loss attributable to the Company’s stockholders	$ (6,994,516)	$ (9,939,514)